Allarity Therapeutics Achieves NASDAQ Compliance Milestone
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company committed to advancing personalized cancer treatments, has recently announced a significant milestone. The company received a formal confirmation from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement under Nasdaq’s Listing Rule 5550(a)(2). This compliance follows a successful period where Allarity’s stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days.
CEO's Statement on Compliance
Thomas Jensen, the CEO of Allarity Therapeutics, expressed optimism and satisfaction regarding the company's recent compliance status. He stated, "We are pleased to report that Nasdaq has recognized our compliance with the minimum bid price requirement. With the resolution of this compliance issue, we can focus on advancing our programs, particularly the stenoparib initiative. Our Phase 2 trial for advanced ovarian cancer has shown encouraging results, and we are committed to developing viable treatment options for patients facing limited alternatives."
The Importance of Stenoparib
Speaking of stenoparib, it is an innovative orally available small-molecule dual-targeted inhibitor specifically designed to inhibit PARP1/2 and Tankyrase 1 and 2. This therapeutic agent has garnered attention for its potential role in treating various types of cancer due to its mechanism of targeting the Wnt signaling pathway. The Wnt/?-catenin signaling mechanism is known to contribute to cancer progression, making stenoparib a promising candidate in contemporary oncology.
Mechanism of Action
By simultaneously impairing both PARP and Wnt pathway activation, stenoparib demonstrates a distinctive therapeutic action. This innovative mechanism is central to the hope that stenoparib could markedly improve treatment outcomes in patients with advanced ovarian cancer.
Allarity's Commitment to Cancer Treatment
Allarity Therapeutics is firmly entrenched in its mission to address unmet medical needs within oncology. The company employs a personalized approach in its drug development, particularly with stenoparib, leveraging its proprietary DRP® companion diagnostic to select patients for ongoing clinical trials. The ongoing Phase 2 clinical trial, registered as NCT03878849, spotlights Allarity's innovative approach to patient-centric drug development.
Research and Development Facilities
Headquartered in the United States with a research facility in Denmark, Allarity is dedicated to ensuring that it stays at the forefront of cancer therapies. The company actively pursues advancements that can provide hope and treatment options to patients struggling with this pervasive illness.
Contact Information and Media Inquiries
For further inquiries, interested parties can reach out through the following contact information:
Investor Relations: investorrelations@allarity.com
Media Contact: Thomas Pedersen, Carrotize PR & Communications, +45 6062 9390, Email: tsp@carrotize.com
Frequently Asked Questions
What does it mean for Allarity to regain NASDAQ compliance?
Regaining NASDAQ compliance allows Allarity to ensure its stock remains listed on the exchange, signaling financial health and stability to investors.
What is stenoparib?
Stenoparib is a dual-targeted PARP and Tankyrase inhibitor being developed for use in advanced ovarian cancer treatments.
Why is stenoparib significant in cancer treatment?
Stenoparib addresses significant gaps in treatment options for advanced ovarian cancer patients, which makes it a crucial research focus for Allarity.
How does Allarity personalize cancer treatment?
Allarity utilizes its DRP® companion diagnostic to tailor treatment plans based on individual patient responses to therapies.
Where is Allarity Therapeutics located?
Allarity Therapeutics is based in the U.S. and also has a research facility in Denmark, which solidifies its presence in the global biopharmaceutical landscape.
